Lexeo Therapeutics (LXEO) CEO sells 10,173 shares in tax-related trade

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S(1)		10,173	D	$6.382(2)	392,483(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $6.22 to $6.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 261,349 Restricted Stock Units.

	/s/ Carole Rosenberg, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lexeo Therapeutics (LXEO) report on this Form 4?

Lexeo Therapeutics reported that CEO Richard Nolan Townsend sold 10,173 shares of common stock. The sale was executed as an open-market transaction and is disclosed as a routine insider trade under the Form 4 filing.

At what price did the Lexeo Therapeutics (LXEO) CEO sell his shares?

The CEO’s sale had a weighted average price of $6.382 per share. A footnote explains the trades occurred in multiple transactions between $6.22 and $6.50, with full price details available upon request from the company or regulators.

Why did the Lexeo Therapeutics (LXEO) CEO sell 10,173 shares?

The Form 4 states the sale of 10,173 shares was made to cover tax obligations arising from the release of restricted stock units. This indicates the transaction was primarily tax-related rather than a discretionary reduction of the CEO’s economic exposure.

How many Lexeo Therapeutics (LXEO) shares does the CEO hold after this transaction?

After the sale, CEO Richard Nolan Townsend directly holds 392,483 shares of Lexeo Therapeutics common stock. A footnote clarifies this total includes 261,349 restricted stock units, reflecting both vested and unvested equity-based compensation.

Does the Lexeo Therapeutics (LXEO) Form 4 mention restricted stock units (RSUs)?

Yes. A footnote specifies the CEO’s reported holdings include 261,349 restricted stock units. The sale of 10,173 shares is described as being made to cover tax obligations related to the release of those RSUs, linking the transaction directly to equity compensation.

Were the Lexeo Therapeutics (LXEO) CEO’s share sales executed in one trade or multiple trades?

The filing explains the sale was executed in multiple trades at prices between $6.22 and $6.50. The reported $6.382 per share reflects a weighted average price, with detailed trade breakdowns available upon request from the CEO through appropriate channels.